<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Candel Therapeutics ( (CADL) ) has provided an announcement. On May 15, 2026, Candel Therapeutics held a live investor webcast in conjunction with the American Urological Association 2026 Annual Meeting to review extended follow-up data from its randomized, placebo-controlled phase 3 trial of aglatimagene besadenovec plus prodrug in men with localized prostate cancer receiving external beam radiation. The data cutoff of March 15, 2026, underpinned presentations indicating accumulating clinical benefit over time, highlighting a potential new approach to enhancing radiotherapy through intratumoral gene delivery, local prodrug activation, and immune priming, and underscoring the company’s bid to strengthen its position in the competitive prostate cancer treatment landscape. The most recent analyst rating on (CADL) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page. Spark’s Take on CADL Stock According to Spark, TipRanks’ AI Analyst, CADL is a Neutral. Score is held down primarily by weak fundamentals (no revenue, sizable losses, and sustained negative free cash flow). Offsetting factors are a strengthened low-debt balance sheet and supportive recent financing that extends runway, while technicals are strong but overbought and valuation remains unfavorable due to ongoing losses. To see Spark’s full report on CADL stock, click here. More about Candel Therapeutics Candel Therapeutics, Inc., listed on Nasdaq as CADL, operates in the biotechnology and therapeutics industry, focusing on gene-based immuno-oncology treatments. Its lead programs include aglatimagene besadenovec (CAN-2409), a viral vector-based therapy designed to be used with oral prodrugs and standard-of-care radiotherapy to treat localized prostate cancer and potentially improve long-term disease control. Average Trading Volume: 1,744,100 Technical Sentiment Signal: Buy Current Market Cap: $652.6M </div>

CADL

SBIO

LABU

Candel Therapeutics announced positive Phase 3 trial data for aglatimagene besadenovec in localized prostate cancer during a webcast at the AUA 2026 Annual Meeting. The data suggests enhanced radiotherapy through gene delivery and immune priming. Analysts rate CADL stock as a Buy with a $25 target, though concerns about fundamentals persist. Candel focuses on gene-based immuno-oncology treatments and has a market cap of $652.6M.

Candel Therapeutics Highlights Phase 3 Prostate Cancer Data